BioSpace News Archive

Thermo Fisher Scientific today announced its Thermo Scientific NanoDrop PC Control software + Security Suite for NanoDrop One/One C can be used in compliance with U.S. Food and Drug Administratio

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Foo

Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). This is the first Phase 3 study of an investigational new drug for the treatment of Meniere’s Disease (MD), a neurotologic disease involving hearing loss, tinn

CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), today announced the completion of two business development initiatives. In the first, CRH completed an accretive transaction whereby the Company has acquired 75% of a gastroenterology (“GI”) anesthesia practice, Lake Lanier Ane

numares appoints Winton Gibbons, as new president of its US subsidiary, numares Group Corp., effective of June 1 st , 2020. Mr. Gibbons will further strengthen commercialization of numares’ products, and help expand the existing network of collaboration partners and investors. This press release features multimedia. View the full release here:

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of the company’s pipeline of small molecule candidates across a range of highly prevalent human diseases. These preclinical programs — AMPKβ2 (

Takara Bio USA, Inc. (TBUSA), a pioneering life science instrument and reagent company and wholly owned subsidiary of Takara Bio Inc., collaborated with bioSyntagma, Inc. and their partners to develop and validate a new high-throughput method for detecting SARS-CoV-2. The method employs automation technology and reagents from TBUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of tho

Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting a poster featuring a post-hoc analysis of a Phase 3 trial of children with ADHD comparing the optimized dose JORNAY PM ® (Methylphenidate HCl) to the study par

SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, today announced a $143 million agreement with the federal government.